RCM
OCUL icon

Rotella Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Rotella Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-18,461
Closed -$388K – 637
2015
Q2 		$388K Buy
+18,461
New +$457K 0.32% 66

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Rotella Capital Management's OCUL Position: Q3 2015 in Review

Rotella Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2015, closing a stake of 18,461 shares — an estimated $388K sold.

Rotella Capital Management first reported a position in OCUL in Q2 2015 and held it in 1 quarter. The position peaked at $388K in Q2 2015. 70 funds tracked by Wall St. Rank hold OCUL as of Q3 2015.

  • Rotella Capital Management reported no remaining Ocular Therapeutix position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 18,461 Ocular Therapeutix shares in Q3 2015, an estimated $388K.
  • Rotella Capital Management first reported a position in Ocular Therapeutix in Q2 2015 and held it in 1 quarter.
  • Rotella Capital Management's Ocular Therapeutix position peaked at $388K in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.